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Abstract
Purpose—Pazopanib, a multi-receptor tyrosine kinase inhibitor targeting primarily vascular 
endothelial growth factor receptors 1-3 (VEGFRs1-3), is approved for advanced soft tissue 
sarcoma and renal cell cancer. Downstream of VEGFR, trametinib is an FDA-approved MEK 
inhibitor used for melanoma. We hypothesized that vertical pathway inhibition using a trametinib 
would synergize with pazopanib in advanced soft tissue sarcoma (STS).
Experimental Design—In an open-label, multicenter, investigator-initiated NCCN-sponsored 
trial, patients with metastatic or advanced STS received pazopanib 800 mg and 2 mg of trametinib 
continuously for 28-day cycles. The primary endpoint was 4-month progression-free survival 
(PFS). Secondary endpoints were overall survival, response rate and disease control rate.
Results—Twenty-five patients were enrolled. The median age was 49 years (range 22–77 years) 
and 52% were male. Median PFS was 2.27 months (95% confidence interval [CI] 1.9–3.9), and 
the 4-month PFS rate was 21.1% (95% CI 9.7–45.9%), which was not an improvement over the 
hypothesized null 4-month PFS rate of 28.3% (p = 0.79). Median overall survival was 9.0 months 
(95% CI 5.7–17.7). A partial response occurred in 2 (8%) of the evaluable patients (95% CI 1.0–
26.0%), one with PIK3CA E542K mutant embryonal rhabdomyosarcoma and another with spindle 
cell sarcoma. The disease control rate was 14/25 (56%; 95% CI 34.9–75.6%). The most common 
adverse events were diarrhea (84%), nausea (64%), and fatigue (56%).
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Conclusion—The combination of pazopanib and trametinib was tolerable without indication of 
added activity of the combination in STS. Further study may be warranted in RAS/RAF aberrant 
sarcomas.
Keywords
Sarcoma; Pazopanib; MEK; Trametinib; VEGF
INTRODUCTION
Soft tissue sarcoma (STS) comprises a heterogenous group of mesenchymal neoplasms, 
including more than 50 subtypes. STS is usually treated using a multidisciplinary approach 
with surgery, radiation therapy, and chemotherapy (1, 2), but the prognosis of patients with 
relapsed or metastatic advanced STS remains poor. Cytotoxic chemotherapy has been the 
mainstay of first- and second-line treatment of these cancers, but patients invariably relapse 
or become refractory to therapy. Pazopanib is a multi-tyrosine kinase receptor inhibitor 
targeting vascular endothelial growth factor receptors 1-3 (VEGFR1-3), c-kit, and platelet-
derived growth factor as its major targets. Though other agents (e.g. trabectedin and 
Eribulin) have recently been approved for select STS subtypes, pazopanib was the first 
targeted therapy to be approved for STS based upon the phase III trial of pazopanib in 
metastatic STS (PALETTE), which reported a median progression-free survival (PFS) 
duration of 4.6 months (3). These patients had received between one and four lines of 
previous therapy, with 50% of patients having received fewer than two lines of previous 
therapy. However, because patients develop resistance to pazopanib monotherapy, 
combination therapies with pazopanib are warranted.
The oncogenic RAS/RAF pathway has been implicated as a mechanism of resistance to 
antiangiogenic therapy (4). Previous work from other groups including ours has used a 
strategy of combination targeting of VEGF signaling with vertical signaling inhibition 
downstream of the VEGFR receptor to improve efficacy (5). Hence, a co-targeting strategy 
with a MAPK inhibitor may overcome resistance to single-agent VEGF inhibition. 
Treatment with sorafenib, an inhibitor of RAF and VEGFR1, dramatically inhibited growth 
of malignant peripheral nerve sheath tumors in vitro, inducing marked inhibition of 
phospho-MEK and phospho-ERK with downstream suppression of cyclin D1 (6). 
Additionally, an in vitro study of the MEK inhibitor U0126 showed inhibited cell 
proliferation and downstream phospho-ERK expression in bone sarcoma and STS cell lines 
in a dose- and time-dependent fashion (7). This has been shown in other malignancies as 
well (8). RAS pathway hyperactivation has been reported in sarcomas as well (9, 10).
On the basis of these findings, we hypothesized that we could increase the impact of 
pazopanib in advanced STS by employing vertical pathway inhibition using a MEK 
inhibitor, trametinib. We used the recommended phase II doses of pazopanib and trametinib 
that we established in a prior dose escalation trial of pazopanib and trametinib in advanced 
solid tumors; in that study, both agents were able to be escalated to their single agent phase 
II dose(11).
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PATIENTS AND METHODS
Patient eligibility
This was an open-label, multicenter [Sidney Kimmel Comprehensive Cancer Center 
(SKCCC) at John Hopkins University (JHU) and The University of Texas MD Anderson 
Comprehensive Cancer Center (MDACC)] trial sponsored by the National Comprehensive 
Cancer Network (NCCN). Patients older than 18 years with advanced, inoperable STS that 
was refractory to standard of care treatment options (or patients who refused standard of 
care treatment options) were eligible. Other eligibility criteria included the presence of 
measurable disease, defined as at least one lesion accurately measured in at least one 
dimension (longest diameter for nonnodal lesions and short axis for nodal lesions) as ≥10 
mm according to spiral computed tomography. In addition, objective evidence of tumor 
progression in the 6-month period preceding initiation of treatment in the trial, as assessed 
by unequivocal progression of objectively measured disease on successive computed 
tomography scans, was a specific requirement for enrollment. Other requirements included 
an Eastern Cooperative Oncology Group performance status ≤1 (or Karnofsky performance 
status ≥60%) and adequate organ function as defined by absolute neutrophil count ≥1,500 
cells/μL, platelet count ≥100,000 cells/μL, international normalized ratio ≤1.2× upper limit 
of normal (unless stabilized with anticoagulation therapy and within the recommended range 
for the desired level of anticoagulation), total bilirubin ≤1.5× upper limit of normal (or, in 
patients with Gilbert syndrome, total bilirubin >1.5× as long as direct bilirubin is normal), 
and serum creatinine ≤1.5× upper limit of normal or creatinine clearance ≥45 mL/minute 
and urine protein to creatinine ratio <1 (or, if >1, 24-hour urine protein <1 g).
Evaluation and treatment
The study was approved by the institutional review boards of the participating sites. The 
study drugs (trametinib and pazopanib) were provided by GlaxoSmithKline (now Novartis). 
Eligible patients were enrolled centrally at the SKCCC at JHU.
Patients in the study received 800 mg of pazopanib and 2.0 mg of trametinib. Protocol 
allowed dose delays or reduction if patients experienced unacceptable side effects and 
adverse reactions. Patients were evaluated every cycle for trial therapy compliance and 
monitoring of adverse events. The National Cancer Institute Common Terminology Criteria 
for Adverse Events version 4.0 was implemented for adverse event monitoring [9]. Disease 
assessments (computed tomography or magnetic resonance imaging) were performed every 
other cycle. Response was evaluated using Response Evaluation Criteria in Solid Tumors 
(RECIST) guidelines version 1.1 [10]. Upon progression of disease, patients were monitored 
for long-term adverse events, new primary tumors, and survival.
One patient in the trial, who had a partial response, had comprehensive genomic profiling 
done on 50 ng of genomic DNA in a Clinical Laboratory Improvement Amendments-
certified laboratory. Another patient, who had Ewing sarcoma, had T200 research panel 
sequencing done as per MD Anderson protocol capturing and sequencing all the exons in 
201 cancer-related genes(12).
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Statistical methods
The primary outcome measure was 4-month PFS rate. Secondary outcome measures 
included overall survival (OS) duration and disease control rate (DCR). Proportions are 
reported with exact 95% binomial confidence intervals (CI). Event time distributions for OS 
and PFS were estimated using the Kaplan-Meier method [1] and CIs were calculated using 
the Brookmeyer-Crowley method. The median follow-up was calculated using the reverse 
Kaplan Meier method. Statistical analyses were performed using SAS version 9.2 (SAS 
Institute Inc, Cary, North Carolina) and R version 3.0.
The benchmark for improvement in the PALETTE study of pazopanib in advanced STS was 
to increase the 6-month PFS rate from 15% to 30%, HR=0.63, (or, assuming exponential 
survival, increasing 4-month PFS from 28% to 45%). The primary endpoint of the current 
study was 4-month PFS. This trial could not be powered to detect a hazard ratio of 0.63, 
however, our pre-specified benchmark for monitoring the study for futility was based on 
achieving a 4-month PFS rate of 45%. The study was designed to stop if we became 75% 
certain that the 4 month PFS was below 45%.
Analysis of sarcoma next generation sequencing data
We analyzed next generation sequencing data from the Cancer Genome Atlas (TCGA) and 
six other sarcoma studies, and figures were generated to show copy number alterations and 
mutations in selected genes in these sarcoma projects. All figure panels were created using 
the cBioPortal(13) for the seven sarcoma data sets available on the portal.
RESULTS
Twenty-five patients with advanced STS were enrolled in the trial. The median age was 49 
years (range 22–77 years). The median number of prior chemotherapies was 3 (range 1–10). 
All 25 patients were evaluable for objective response, and the baseline characteristics and 
histologies are outlined in Table 1. Thirteen patients (52%) were male. Six patients (24%) 
had leiomyosarcoma and four patients (16%) each had liposarcoma [1 pleiomorphic 
liposarcoma, and 3 de-differentiated liposarcoma], Ewing sarcoma, and spindle cell 
sarcoma. Other subtypes included rhabdomyosarcoma, epithelioid fibrosarcoma, 
hemangiopericytoma, pleomorphic sarcoma, synovial sarcoma, dedifferentiated 
chondrosarcoma, and malignant peripheral nerve sheath tumor associated with NF1 
syndrome (n = 1 each).
Clinical outcomes
Partial responses occurred in 2 (8%) of the evaluable patients (95% CI 1.0–26.0%). No 
patient achieved a complete response. The DCR was 14/25 (56%; 95% CI 34.9%–75.6%). 
Stable disease was the best response in 12 (48%) and progressive disease was the response 
in 11 patients (44 %).
Survival outcomes
Patients who withdrew early from the treatment protocol were censored for PFS at the time 
of withdrawal. All other patients were followed for OS for 3 years, or until death, regardless 
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time on study therapy. Follow-up was 95% complete through 16 months, with only one 
censored patient after month 20 (Figure 1). The median follow-up, calculated as the 50%-
point of the censoring function, was 25.56 months (ranging from 1.8–25.6 months) The 
overall percentage censored for OS was 12% (3 patients).
PFS and OS are shown in Figure 2. The median PFS was 2.27 months (95% CI 1.9–3.9). 
The 4-month PFS rate was 21.1% (95% CI 9.7–45.9%), which was not an improvement over 
the hypothesized null 4-month PFS rate of 28.3% (p = 0.79). Median OS was 9.0 months 
(95% CI 5.7–17.7).
Adverse events
All relevant grade 1 and 2 toxic effects related to the protocol and all grade 3 and 4 toxic 
events and dose-limiting toxicities are summarized in the Table 2. The most common 
adverse events attributable to study drug were diarrhea (84%), nausea (64%), and fatigue 
(56%) and generally low-grade. Other toxicities that were attributable to drug and grade ¾ 
included anemia (8%), hypokalemia (12%), anemia (12%), and thrombocytopenia (16%). 
The left ventricular ejection fraction was transiently reduced in one patient who had 
previously received high cumulative exposures to doxorubicin and an IGF1R inhibitor, but 
the ejection fraction returned to normal after the pazopanib/trametinib combination was 
discontinued.
Response
Two patients (8%) achieved partial response and 12 patients had stable disease per RECIST. 
One of the patients who achieved partial response, who had a sinonasal embryonal 
rhabdomyosarcoma, had a 59% tumor size reduction (Figure 3E–H). Next-generation 
sequencing analysis of the patient revealed PIK3CA E542K aberration (14). The 
implications of this mutation are discussed below. The other patient had a 63% tumor size 
reduction (Figure 3A–D). This patient had undifferentiated sarcoma and did not have any 
molecular testing done owing to nonavailability of tissue.
Ewing sarcoma responses have been noted with single-agent pazopanib (15–17). However, 
we did not see any responses to the combination of pazopanib and trametinib 
(GSK1120212) in patients with Ewing sarcoma. Next-generation sequencing of the 
molecular profile of one of the patients with Ewing sarcoma was compared with a previous 
patient who had a response to pazopanib in our clinic, and we found that three genes 
(FGFR3, FGFR4, and FLT4) were amplified only in the responder (Table 3).
Dose Reductions
Eight patients/25 patients (32%) required dose reductions of the pazopanib or trametinib 
beyond the first cycle. The dose was reduced in 5 patients treated with pazopanib (from 800 
mg to 600 mg) and 4 patients who received trametinib, decreasing 1.5 mg. Twelve of 
twenty-five were safely maintained at the recommended phase 2 dose of both the drugs. 
100% dose intensity for pazopanib was 22,400 mg and trametinib is 56 mg.
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Next generation sequencing data of sarcomas
Because the trial targeted the MAPK pathway and one of the exceptional responders 
harbored the PIK3CA E542K mutation, we analyzed sequencing data from the TCGA and 
six other sequencing projects available on cBioPortal(13) for aberrations in the following 
genes: BRAF, NRAS, KRAS, MAPK1, MAPK3, MAP2K1 and PIK3CA. Mutations and 
copy number alterations from seven sarcoma studies are depicted in Figure 4. Interestingly, 
most of the alterations in these genes were mutually exclusive, and PIK3CA alterations 
showed various frequencies in these studies, with 41% cases altered in uterine 
carcinosarcoma.
DISCUSSION
The FDA approval of pazopanib for the treatment of STS has opened up several possible 
combinations with this agent, given that nearly all patients experience disease progression 
with monotherapy. Combinations involving VEGF-based multikinase tyrosine kinase 
inhibitors are a challenge because many other targeted therapies have overlapping toxicities. 
There is a need to balance clinical benefit with clinical toxicity. In the current study, the 
combination of pazopanib and trametinib was reasonably well tolerated, although several 
patients had dose reductions. Clinical responses were observed, but did not meet the primary 
study endpoint of reduced 4-month PFS.
In-depth analysis of one of the exceptional responders revealed a PIK3CA E542K aberration 
in a patient with sinonasal rhabdomyosarcoma. This patient had previously received 
treatment with a PI3K inhibitor, but the tumor had progressed. It is difficult to determine 
whether the tumor responded to pazopanib or trametinib in our protocol, but evidence from 
the literature suggests that the combination of agents could have contributed. RAS pathway 
overactivity has been shown in rhabdomyosarcoma (18), and the RAS/RAF pathway is one 
of the mechanisms of resistance to P13K pathway inhibition. In addition, PI3K activation 
occurs in more than 80% of rhabdomyosarcomas, and MAPK pathway co-activation occurs 
in 46% of embryonal rhabdomyosarcomas, suggesting that dual blockade could be an 
effective treatment strategy (19). The multi-kinase VEGF inhibitor could have potentiated 
the MEK inhibition in this patient, leading to the partial response. Interestingly, it has also 
been shown that pazopanib suppresses the PI3K pathway in rhabdomyosarcomas (10).
In-depth sequencing of Ewing sarcoma from a patient who responded to pazopanib in our 
clinic compared with the non-responder from the current study revealed divergence in the 
genotype of Ewing sarcoma in a three-gene signature consisting of FGFR3, FGFR4, and 
FLT4, which are all targets for pazopanib. These observations are strictly hypothesis-
generating, but they may warrant further studies comparing pazopanib responders with non-
responders. Ewing sarcoma is a translocation-positive sarcoma, and it would be helpful to 
identify mechanisms of response and resistance in these patients (20–22). In patients with 
Ewing sarcoma in the current study, the combination of the pazopanib and trametinib was 
tolerated but did not add any benefit to pazopanib as a single agent. However, we treated 
only 4 patients with Ewing’s sarcoma in this trial.
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Toxic effects in our trial included diarrhea, which was grade 1/2 in 18 patients and grade 3 in 
three patients which was consistent with expected toxicity from other trials. This was 
managed by loperamide and atropine/diphenoxylate. The unexpected reduction of left 
ventricular ejection fraction in a patient with Ewing sarcoma was reviewed in detail. This 
patient had received heavy prior treatment with doxorubicin, a anthracycline known to 
increase the risk of cardiomyopathy, and an IGF1R inhibitor that is unlikely to have 
contributed. Though the toxic effect could have resulted from an interaction between MEK 
inhibition and chemotherapy-induced cardiomyocyte damage induced by prior therapies, our 
study cannot conclusively address this question. The adverse event was attributed as possibly 
related to study drugs, and the patient withdrew from the protocol.
The current study demonstrates the feasibility and efficiency of performing a phase II trial 
through the National Comprehensive Cancer Network. Two sites, major cancer referral 
centers, allowed very easy accrual of patients. However, one of the major limitations of the 
current study is that it included all diagnoses of STS and there was no selection for tumors 
with hyperactivity of the RAS/RAF pathway. A recently published trial noted that MEK 
inhibitors as monotherapy did not have any activity in STS (23). The median PFS reported in 
this study is 2.27 months compared to 4.6 months in the PALETTE study. Firstly, the 
number of prior therapies and the eligibility criteria for the trial varied. This trial was written 
as a phase 1 trial and this sarcoma cohort was the expansion part. The eligibility criteria for 
trial entry for the PALETTE Phase 3 trial were more rigorous than this Phase 1 trial. 
Secondly, this trial specifically required objective evidence of tumor progression in the 6-
month period preceding initiation of treatment in the trial, as assessed by unequivocal 
progression of objectively measured disease on successive computed tomography scans. 
This could have probably selected for aggressive biology patients for this trial. Thirdly, 
PALETTE ineligible patients with histology such as embryonal rhabdomyosarcoma, 
liposarcoma and Ewing’s sarcoma were included on the trial. In addition a recent study by 
Nakano et al notes that PALLETTE study ineligible patients might have worse prognosis on 
pazopanib than PALETTE-eligible patients and our study confirms this (24). The resistance 
mechanisms to VEGF inhibitors such as pazopanib are complex. Although pathways in 
sarcomas like VEGF have often been depicted as linear, clearly there is a complicated 
interaction among signaling elements (25, 26). A recent study showed the mTOR inhibitor 
could overcome pazopanib resistance(27). Several trials with pazopanib combinations are 
ongoing, including pazopanib + vorinostat (HDAC inhibitor; NCT01339871), pazopanib + 
everolimus (mTOR inhibitor; NCT01430572), pazopanib + lapatinib or trastuzumab (Her2 
inhibitors; NCT01454804), pazopanib + gemcitabine (NCT01532687), pazopanib + 
pemetrexed or crizotinib (NCT01548144), and pazopanib + topotecan (NCT02357810). The 
results of these trials may be helpful in evaluating which combination is better than single-
agent pazopanib in STS.
In addition, although pazopanib as a targeted agent is approved for STS, the biomarkers of 
response or resistance are unknown, and the responses to such antiangiogenic agents are 
complex. As noted above, we identified a three-gene signature in a pazopanib responder that 
was not present in a non-responder, and these findings may warrant further study. As MEK 
inhibitors are active in RAF/RAS pathway-activated melanoma (28), a trial that includes 
STS patients harboring a RAF/RAS-overactive genotype may yield better results. Our 
Subbiah et al. Page 7
Clin Cancer Res. Author manuscript; available in PMC 2018 February 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
analysis of sequencing data from the TCGA and other projects shows that RAS/RAF is 
activated in a subset of sarcoma patients. Further evaluation of the combination of pazopanib 
and a MEK inhibitor specifically in RAS/RAF-activated tumors such as 
rhabdomyosarcomas, in a randomized design comparing pazopanib monotherapy with the 
combination, is one future goal.
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STATEMENT OF TRANSLATIONAL RELEVANCE
Pazopanib, US FDA approved for advanced soft tissue sarcoma is a multi-tyrosine kinase 
receptor inhibitor targeting vascular endothelial growth factor receptors 1-3 (VEGFR1-3), 
c-kit, and platelet-derived growth factor as its major targets. However, because patients 
develop resistance to pazopanib monotherapy, combination therapies with pazopanib are 
warranted. The oncogenic RAS/RAF pathway has been implicated as a mechanism of 
resistance to antiangiogenic therapy. Previous work from other groups including ours has 
used a strategy of combination targeting of VEGF signaling with vertical signaling 
inhibition downstream of the VEGFR receptor to improve efficacy. Hence, a co-targeting 
strategy with a MAPK inhibitor may overcome resistance to single-agent VEGF 
inhibition. We hypothesized that we could increase the impact of pazopanib in advanced 
soft tissue sarcoma by employing vertical pathway inhibition using a MEK inhibitor, 
trametinib and report the results of the Phase 1b/2 trial.
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Figure 1. 
Kaplan-Meier estimate of potential follow-up times.
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Figure 2. 
A: Progression-free survival (B) overall survival curves Two-month, 4-month, and 6-month 
survival rates and 95% confidence intervals are shown.
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Figure 3. 
Images showing response of sarcomas to pazopanib and GSK1120212 in two patients. (A, 
C) Baseline imaging in a patient with spindle cell sarcoma. (B, D) Re-staging scans during 
the trial showing a reduction in disease. (E, G) Baseline imaging in a patient with a sinonasal 
embryonal rhabdomyosarcoma. (F, H) Re-staging scans during the trial showing a reduction 
in disease.
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Figure 4. 
Analyses of the SARCOMA TCGA data for aberrations in the following genes BRAF, 
NRAS, KRAS, MAPK1, MAPK3, MAP2K1 and P1K3CA. Mutations and copy number 
alterations from seven sarcoma studies are depicted.
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Figure 5. 
Responses per RECIST 1.1 Two partial responses were seen. Patients 3, 12, and 14 had new 
lesions and hence progressive disease.
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Table 1
Baseline characteristics and best responses of patients enrolled in the trial (n = 25).
Characteristic No. of patients (%)
Median age (range) 49 years (22–77 years)
Sex
 Male 13 (52)
 Female 12 (48)
Median no. of prior lines of chemotherapy (range) 3 lines (1–10 lines)
Median no. of prior radiation treatments (range) 1 treatment (0–2 treatments)
Sarcoma subtype
 Leiomyosarcoma 6 (24)
 Liposarcomaa 4 (16)
 Ewing sarcoma 4 (16)
 Spindle cell sarcoma 4 (16)
 Otherb 7 (28)
Best response
 Partial response 2 (8)
 Stable disease 12 (48)
 Progressive disease 11 (44)
a
Three De-differentiated liposarcoma and one pleiomorphic liposarcoma. One De-differentiated liposarcoma had focal rhabdoid features.
bSinonasal embryonal rhabdomyosarcoma, epithelioid fibrosarcoma, hemangiopericytoma, pleomorphic sarcoma, synovial sarcoma, 
dedifferentiated chondrosarcoma, and neurofibrosarcoma (n = 1 each).
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Table 3
Amplification of three genes in patient with Ewing sarcoma from a previous study who responded to treatment 
with pazopanib, compared with a patient with Ewing sarcoma in the current study who did not respond to 
combination treatment.
Gene
Amplification
Ewing sarcoma responder Ewing Sarcoma nonresponder
FGFR3 8.7 2.6
FGFR4 5.2 2.8
FLT4 4.8 2.6
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